Vir Biotechnology to Participate in Upcoming Investor Conferences

Vir Biotechnology, Inc. (Nasdaq: VIR) has announced its participation in various investor conferences scheduled for March 2026. Chief Executive Officer Marianne De Backer is set to engage in two prominent fireside chats: the TD Cowen 46th Annual Health Care Conference on March 2 in Boston, and the Leerink Partners Global Healthcare Conference on March 10 in Miami. Additionally, members of the management team will be available for one-on-one meetings at the Barclays 28th Annual Global Healthcare Conference on March 12 in Miami.

These conferences will provide an opportunity for Vir to showcase its innovations and strategic vision in the biopharmaceutical sector, particularly as it continues to focus on harnessing the immune system to combat serious infectious diseases and cancer. The live webcasts of the fireside chats will be accessible through the company’s investor website, with archived versions available for 30 days afterward.

Vir Biotechnology is at the forefront of developing therapies, with a portfolio that emphasizes chronic hepatitis delta treatment and innovative oncologic solutions through its proprietary PRO-XTEN® technology. This dual-masked T-cell engager platform is designed to target solid tumor indications effectively. The company is also advancing various preclinical programs that span a wide spectrum of infectious diseases and cancer.

Investors can stay informed about the company’s developments via its website, where essential updates are routinely posted. This proactive approach aims to enhance transparency and provide stakeholders with timely information about Vir's progress and strategic initiatives within the fast-evolving health care landscape. For further inquiries, media and investor relations contacts have been provided for direct communication.

Vir Biotechnology, Inc. (Nasdaq: VIR) stands poised for significant visibility and potential investor interest with its participation in several upcoming healthcare conferences in March. This period could serve as an opportune moment for investors to assess the company's strategic directions and advancements in its clinical-stage portfolio.

The company's management, particularly CEO Marianne De Backer, will engage stakeholders during fireside chats at the TD Cowen 46th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. Given De Backer’s extensive background in biotechnology, her insights could provide valuable information about Vir’s ongoing projects and strategies, particularly concerning its focus on innovative treatments for serious infectious diseases and cancer.

Investors should pay close attention to the discussions regarding Vir's proprietary PRO-XTEN® technology, particularly its dual-masked T-cell engagers in solid tumor indications. This platform could represent a significant advancement in oncology treatments and might prove appealing to investors looking for companies at the forefront of biopharmaceutical research.

Furthermore, management’s availability for one-on-one meetings at the Barclays Global Healthcare Conference offers a unique opportunity for investors to glean detailed insights about Vir's pipeline and market strategies directly from the team driving the company's vision.

The live webcasts of the fireside chats should not be missed, as they allow investors to engage with the content remotely. With a wealth of clinical programs in its pipeline, Vir’s commitment to discovering transformative therapies positions it attractively in a competitive market.

In summary, investors should consider monitoring Vir Biotechnology's developments closely during these conferences. The insights shared at these events may provide valuable information to assess the future potential of the company's novel therapies and overall market position.